Skip to content
Screener

Denali Therapeutics Inc. DNLI Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$3.6MBeat by $1.4M
EPS-$0.68Miss by $0.17
Revenue estimate$2.2M
EPS estimate-$0.51

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$12.2M
EPS estimate-$0.37

Financials

Q2 2026

Income statement

See full
Revenue$3.6M—
Gross profit$3.5M—
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.21B+67.9%
Enterprise value$3.04B+67.6%
P/S889.7×—

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0×0.0×
Current ratio8.4×-1.9×

Segments

By product

See full
Milestone Triggered$25.0M0.0%
Milestone Payment$2.5M0.0%
Option Fee Payment$2.5M+100%

FAQ

When did Denali Therapeutics Inc. report Q2 2026 earnings?
Denali Therapeutics Inc. (DNLI) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Denali Therapeutics Inc.'s Q2 2026 revenue and EPS?
Denali Therapeutics Inc. reported revenue of $3.6M and eps of $-0.68 for Q2 2026.
Did Denali Therapeutics Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $2.2M by $1.4M. EPS missed the consensus estimate of $-0.51 by $0.17.
How did Denali Therapeutics Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 5.6% from $-0.72.
Where can I find Denali Therapeutics Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001714899-26-000096) and the 10-Q periodic report (0001714899-26-000097) directly on SEC EDGAR. The filing index links above go to sec.gov.